CT-0596
/ CARsgen
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
November 04, 2025
A first-in-human study of CT0596, an allogeneic CAR T-cell therapy targeting BCMA, in patients with relapsed/refractory multiple myeloma
(ASH 2025)
- P1 | "Following lymphodepletion regimen consisting of fludarabine (30 mg/m2) and cyclophosphamide(500 mg/m2) for 3 consecutive days, CT0596 was administered at escalating doses of 1.5×108, 3.0×108 or4.5×108 CAR-positive T cells using i3+3 dose-escalation design. No patients got progression disease, and Pat 01has ongoing sCR and MRD negative for nearly 6 months. CAR T cell expansion was observed in all 8patients.ConclusionThese initial results from this study of CT0596 support the feasibility and safety of allogeneic CAR T-celltherapy for RR MM, thereby warranting further exploration in larger-scale trials."
CAR T-Cell Therapy • Clinical • First-in-human • P1 data • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Leukopenia • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia • B2M • KLRC1
December 07, 2025
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting
(PRNewswire)
- "This clinical trial (NCT06718270) enrolled 8 patients with R/R MM in the dose-escalation phase who received CT0596 infusion....Six patients achieved a partial response (PR) or better: 3 achieved complete response/stringent complete response (CR/sCR) (all in the full-dose lymphodepletion group), 1 achieved very good partial response (VGPR), and 2 achieved PR. Among the 6 patients who received full-dose lymphodepletion, 5 achieved PR or better. Six patients in the full-dose lymphodepletion group achieved minimal residual disease (MRD)-negativity at Week 4....The company plans to initiate a Phase 1b registrational study for CT0596 in 2026."
New P1 trial • P1 data • Multiple Myeloma
November 03, 2025
Data for CT0596 in Relapsed/Refractory Multiple Myeloma
(PRNewswire)
- "Five patients achieved partial response (PR) or above: 3 achieved complete response / stringent complete response (CR/sCR) (all of whom had received the full dose of lymphodepletion), 1 achieved PR, and 1 achieved very good partial response (VGPR). Six patients achieved minimal residual disease (MRD)-negativity at Week 4. No patients got progression disease. Pat 01 has ongoing sCR and MRD negative for nearly 6 months. CAR-T cell expansion was observed in all 8 patients. No dose-limiting toxicities (DLT), treatment discontinuations, or deaths were observed."
Clinical data • Multiple Myeloma
October 19, 2025
Case Report | Preliminary Clinical Data of CARsgen’s Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
(The Manila Times)
- "pPCL-01: A 62-year-old male with IgG-λ type experienced poor disease control and rapid progression....Following this infusion, he developed Grade 2 CRS, Grade 4 cytopenia, and a lung infection, but recovered after supportive treatment including tocilizumab, corticosteroids, autologous stem cell infusion, and anti-infective therapy....pPCL-02:A 70-year-old male with κ light chain had previously been treated with triple classes of drugs (proteasome inhibitor, immunomodulatory agent, and CD38 monoclonal antibody). The patient developed Grade 1 CRS, Grade 4 neutropenia, and thrombocytopenia following lymphodepletion and CAR-T cell infusion."
Clinical data • Plasma Cell Leukemia
October 06, 2025
Beyond R/R MM, further investigation is planned in additional plasma cell malignancies...
(HKEXnews)
- "The Company anticipates submitting an Investigational New Drug (IND) application in the second half of 2025."
IND • Plasma Cell Leukemia
October 06, 2025
The board of directors of the Company (the “Board”) announces that the Company will present the clinical data of CT0596 (an allogeneic CAR T-cell product candidate against BCMA) at the 67th Annual Congress of the American Society of Hematology (“ASH”)
(HKEXnews)
- "Abstracts and further details will be announced after November 3, 2025 Eastern Time."
Clinical data • Hematological Malignancies
October 01, 2025
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
(clinicaltrials.gov)
- P1 | N=24 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2024 ➔ Jul 2025
Enrollment open • Trial initiation date • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia
August 02, 2025
A Study of CT0596 in Plasma Cell Leukemia
(clinicaltrials.gov)
- P1 | N=27 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Leukemia • Oncology • Plasma Cell Leukemia
May 23, 2025
A Study of CT0596 in Plasma Cell Leukemia
(clinicaltrials.gov)
- P1 | N=27 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P1 trial • Hematological Malignancies • Leukemia • Oncology • Plasma Cell Leukemia
May 11, 2025
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
(PRNewswire)
- P1 | N=24 | NCT06718270 | "As of May 6, 2025, 8 patients with R/R MM who had received at least three prior lines of therapy were enrolled and infused with CT0596 following lymphodepletion with the FC regimen (fludarabine 22.5-30 mg/m² and cyclophosphamide 350-500 mg/m²). Key findings from up to four months of follow-up include:...(i) Among 5 patients who completed the first efficacy assessment at Week 4, 3 patients (60%) achieved stringent complete response/complete response (sCR/CR), and 4 patients (80%) achieved minimal residual disease (MRD)-negativity in the bone marrow; (ii) Early efficacy data from 2 patients at Day 14 showed reductions in measurable lesions by ≥92% and ≥65%, respectively; (iii) 1 patient had not yet reached the protocol-specified efficacy assessment timepoint. All sCR/CR patients remained in ongoing responses, including the first patient who completed the four-month follow-up."
P1 data • Multiple Myeloma
December 12, 2024
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University
CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology
1 to 11
Of
11
Go to page
1